MERCY-SHIPS
H.E. President of Senegal Macky Sall has inaugurated the world’s largest purpose-built hospital ship and committed to accelerate access to surgical, obstetric and anesthetic care for the nations of Africa. Ceremonies commemorated more than 30 years of service in Africa. International humanitarian organization Mercy Ships and its partners in Africa used the opportunity to come together in an unprecedented and strategic effort to improve access to safer surgery across the continent through a series of milestone events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005472/en/
Representatives from Cameroon, the Union of Comoros, Congo Brazzaville, The Gambia, Guinea-Bissau, and Senegal, gathered on board the Global Mercy to approve a strategic road map to improve surgical care for African nations by 2030, where an estimated 93% of sub-Saharan Africa still lack access to safe surgery.
H.E. President Macky Sall greeted the Heads of State, saying, “We, heads of states present this day, have adopted the Dakar Declaration, which is the result of the meticulous work of our ministers and experts on access to surgical, obstetric and aesthetic care. As President in Office for the African Union, I commit to bring the Dakar Declaration to the summit of heads of state and African governments.”
Gert van de Weerdhof, Mercy Ships Chief Executive Officer said, “At the end of a difficult week for Senegal and for all of us after the tragic events that happened; today, I want to greet you all on this special day here in Dakar, Senegal. The inauguration of the Global Mercy is only one part of the reason we celebrate today. Big decisions have been made here in Dakar.”
President of the Union of the Comoros, Azali Assoumani said, “I pay tribute to Senegal as well as the personnel of Mercy Ships for their commitment to this mission. I applaud this model cooperation contributing to the strengthening of our surgical, obstetric, and anesthetic systems in Africa.”
The Dakar Declaration is an historic agreement following foundational discussions from an International Symposium in Senegal held May 4 – 6, 2022 where experts and ministers of health from 29 African nations met to put forward their commitment to advancing access to surgical, obstetric, and anesthetic care. The result of the Symposium brought a fresh initiative to draft a clear path toward safer and wider access to surgical care in Africa by 2030. Symposium members shared knowledge of their countries’ surgical care situations, addressed gaps and challenges in their national surgical, obstetric and anesthetic plans, and developed new strategies for implementation and capacity building. Prior to the International Symposium, a baseline assessment was carried out with each country and evaluated by a scientific committee.
A first of its kind in Africa, this study has so far collected data about the availability, access, and operation of surgical, obstetric, and anesthetic healthcare systems in 29 of the 47 nations of WHO’s sub-Saharan African region. The survey provides critical insights into Africa’s healthcare systems from the perspective of district hospitals, particularly in the area of surgery. The World Health Organization will leverage the results of the study to complete the ongoing situational analysis of clinical and hospital services, as well as develop and finalize the regional strategy for strengthening clinical and hospital services in Africa.
The comprehensive preliminary report developed by members of the scientific committee led to the drafting of a roadmap to scale up investment in the strengthening of surgical, obstetric, anesthetic, and nursing care in Africa, in line with the Sustainable Development Goals (SDG). A draft Dakar Declaration was prepared and endorsed by the Ministers of Health and approved by visiting African Heads of State.
The new hospital ship, Global Mercy ™ is 174 meters long, 28.6 meters wide and has space for 200 patients, six operating rooms, one laboratory, general outpatient clinics, a dental clinic, and an eye clinic. The hospital decks cover a total area of 7,000 square meters and contain the latest training facilities. When in full service, the ship will be able to accommodate up to 950 people when docked, including crew members and volunteers from all over the world.
A recording of the inauguration ceremony can be found here: https://www.youtube.com/watch?v=HylOGBYaX-0 .
ABOUT MERCY SHIPS:
Global health for the last two decades has focused on individual diseases, while surgical care in low-resource countries has not received the attention it needs. Lack of surgical care resulted in almost 17 million deaths annually.
Mercy Ships is an international faith-based organization that operates hospital ships to deliver free, world-class healthcare services, medical capacity building, and health system strengthening to those with little access to safe surgical care. Since 1978, Mercy Ships has worked in more than 55 countries, with the last three decades focused entirely on partnering with African nations. Each year, volunteer professionals from over 60 countries serve on board the world’s two largest non-governmental hospital ships, the Africa Mercy® and the Global Mercy™. Professionals such as surgeons, dentists, nurses, health trainers, cooks, and engineers dedicate their time and skills to the cause. Mercy Ships has offices in 16 countries and an Africa Bureau. For more information, visit mercyships.org and follow us @MercyShips on social media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005472/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
